These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
269 related articles for article (PubMed ID: 17963264)
1. FOLFOX in patients aged between 76 and 80 years with metastatic colorectal cancer: an exploratory cohort of the OPTIMOX1 study. Figer A; Perez-Staub N; Carola E; Tournigand C; Lledo G; Flesch M; Barcelo R; Cervantes A; André T; Colin P; Louvet C; de Gramont A Cancer; 2007 Dec; 110(12):2666-71. PubMed ID: 17963264 [TBL] [Abstract][Full Text] [Related]
2. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study. Tournigand C; Cervantes A; Figer A; Lledo G; Flesch M; Buyse M; Mineur L; Carola E; Etienne PL; Rivera F; Chirivella I; Perez-Staub N; Louvet C; André T; Tabah-Fisch I; de Gramont A J Clin Oncol; 2006 Jan; 24(3):394-400. PubMed ID: 16421419 [TBL] [Abstract][Full Text] [Related]
3. A phase II trial of modified FOLFOX as first-line chemotherapy in advanced colorectal cancer. Xiong JP; Zhang L; Zhong LX; Qiu F; Xu J; Tao QS; Xiang XJ; Yu F; Tang XM Anticancer Drugs; 2007 Oct; 18(9):1103-7. PubMed ID: 17704661 [TBL] [Abstract][Full Text] [Related]
4. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. Chibaudel B; Maindrault-Goebel F; Lledo G; Mineur L; André T; Bennamoun M; Mabro M; Artru P; Carola E; Flesch M; Dupuis O; Colin P; Larsen AK; Afchain P; Tournigand C; Louvet C; de Gramont A J Clin Oncol; 2009 Dec; 27(34):5727-33. PubMed ID: 19786657 [TBL] [Abstract][Full Text] [Related]
5. The efficacy and toxicity of FOLFOX regimen (a combination of leucovorin and fluorouracil with oxaliplatin) as first-line treatment of metastatic colorectal cancer. Matsushita H; Tsuboi K; Honda I; Kato N; Okochi O; Kobayashi D; Hattori M Gan To Kagaku Ryoho; 2009 May; 36(5):797-801. PubMed ID: 19461180 [TBL] [Abstract][Full Text] [Related]
6. FOLFOX4 in the treatment of metastatic colorectal cancer in elderly patients: a prospective study. Berretta M; Cappellani A; Fiorica F; Nasti G; Frustaci S; Fisichella R; Bearz A; Talamini R; Lleshi A; Tambaro R; Cocciolo A; Ristagno M; Bolognese A; Basile F; Meneguzzo N; Berretta S; Tirelli U Arch Gerontol Geriatr; 2011; 52(1):89-93. PubMed ID: 20211502 [TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of modified FOLFOX6 for treatment of metastatic or locally advanced colorectal cancer. A single-institution outcome study. Matsumoto S; Nishimura T; Kanai M; Mori Y; Nagayama S; Kawamura J; Nomura A; Miyamoto S; Kitano T; Ishiguro H; Yanagihara K; Teramukai S; Sakai Y; Chiba T; Fukushima M Chemotherapy; 2008; 54(5):395-403. PubMed ID: 18781065 [TBL] [Abstract][Full Text] [Related]
8. Feasibility of oxaliplatin and infusional fluorouracil/leucovorin (FOLFOX4) for Japanese patients with unresectable metastatic colorectal cancer. Fuse N; Doi T; Ohtsu A; Takeuchi S; Kojima T; Taku K; Tahara M; Muto M; Asaka M; Yoshida S Jpn J Clin Oncol; 2007 Jun; 37(6):434-9. PubMed ID: 17656481 [TBL] [Abstract][Full Text] [Related]
9. FOLFOX (oxaliplatin and 5 fluorouracil/leucovorin) in patients with untreated metastatic gastric adenocarcinoma Phase II study. Mohammad HA; Magdy FM; Mahmoud OM Indian J Cancer; 2011; 48(4):460-5. PubMed ID: 22293261 [TBL] [Abstract][Full Text] [Related]
10. A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy. Hecht JR; Pillai M; Gollard R; Heim W; Swan F; Patel R; Dreiling L; Mo M; Malik I Clin Colorectal Cancer; 2010 Apr; 9(2):95-101. PubMed ID: 20378503 [TBL] [Abstract][Full Text] [Related]
11. Oxaliplatin combined with continuous infusion of 5-fluorouracil as first-line chemotherapy in patients with metastatic or recurrent gastric adenocarcinoma. Lim JY; Cho JY; Oh KJ; Choi SH; Lee SI; Jeung HC Chemotherapy; 2009; 55(4):200-6. PubMed ID: 19451710 [TBL] [Abstract][Full Text] [Related]
12. Oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX-4) as salvage chemotherapy in patients with pretreated colorectal cancer. Shitara K; Munakata M; Muto O; Kasai M; Okada R; Mitobe S; Sakata Y Gan To Kagaku Ryoho; 2007 Jul; 34(7):1079-84. PubMed ID: 17637544 [TBL] [Abstract][Full Text] [Related]
13. Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer. Ramanathan RK; Clark JW; Kemeny NE; Lenz HJ; Gococo KO; Haller DG; Mitchell EP; Kardinal CG J Clin Oncol; 2003 Aug; 21(15):2904-11. PubMed ID: 12885808 [TBL] [Abstract][Full Text] [Related]
14. Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure. Boige V; Malka D; Elias D; Castaing M; De Baere T; Goere D; Dromain C; Pocard M; Ducreux M Ann Surg Oncol; 2008 Jan; 15(1):219-26. PubMed ID: 17896145 [TBL] [Abstract][Full Text] [Related]
15. Use of the folinic acid/5-fluorouracil/irinotecan (FOLFIRI 1) regimen in elderly patients as a first-line treatment for metastatic colorectal cancer: a Phase II study. François E; Berdah JF; Chamorey E; Lesbats G; Teissier E; Codoul JF; Badetti JL; Hébert C; Mari V Cancer Chemother Pharmacol; 2008 Nov; 62(6):931-6. PubMed ID: 18273618 [TBL] [Abstract][Full Text] [Related]
16. Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first-line treatment of metastatic colorectal cancer. Ashley AC; Sargent DJ; Alberts SR; Grothey A; Campbell ME; Morton RF; Fuchs CS; Ramanathan RK; Williamson SK; Findlay BP; Pitot HC; Goldberg RM Cancer; 2007 Aug; 110(3):670-7. PubMed ID: 17559146 [TBL] [Abstract][Full Text] [Related]
17. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. Al-Batran SE; Hartmann JT; Probst S; Schmalenberg H; Hollerbach S; Hofheinz R; Rethwisch V; Seipelt G; Homann N; Wilhelm G; Schuch G; Stoehlmacher J; Derigs HG; Hegewisch-Becker S; Grossmann J; Pauligk C; Atmaca A; Bokemeyer C; Knuth A; Jäger E; J Clin Oncol; 2008 Mar; 26(9):1435-42. PubMed ID: 18349393 [TBL] [Abstract][Full Text] [Related]
18. Oxaliplatin in patients with metastatic colorectal cancer: efficacy and pharmacokinetics parameters. Burz C; Berindan-Neagoe I; Balacescu O; Todor N; Pelau D; Floares C; Kacso G; Tanaselia C; Ursu M; Vlase L; Leucuta SE; Cristea V; Irimie A J BUON; 2010; 15(2):263-9. PubMed ID: 20658719 [TBL] [Abstract][Full Text] [Related]
19. Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity. Milla P; Airoldi M; Weber G; Drescher A; Jaehde U; Cattel L Anticancer Drugs; 2009 Jun; 20(5):396-402. PubMed ID: 19287306 [TBL] [Abstract][Full Text] [Related]
20. [Clinical significance of bolus 5-fluorouracil for recurrent or metastatic colorectal cancer treated with FOLFOX+ BevacizumabTherapy]. Yoshida Y; Hasegawa J; Nishimura J; Hirota M; Kim Y; Nezu R Gan To Kagaku Ryoho; 2011 Aug; 38(8):1293-6. PubMed ID: 21829066 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]